Subscribe to Email Alerts
Menu
About Us
About INOVIQ
Market Opportunity
Board
The Team
Partners
Distributors
Compliance
Careers
Technology
Our Science
NETs Platform
SubB2M Platform
BARD1 Biomarker Technology
hTERT ICC Assay
Intellectual Property
Publications
Resources
Business Development
Products
Our Products
EXO-NET® Pan-Exosome
Product Overview
Technical Information
Data & Figures
Ordering
hTERT ICC Test
Pipeline
Development Pipeline
SubB2M CA15-3
SubB2M CA125
Exo-Ovarian Cancer Test
Exosome Therapeutics
Investors
Investor Overview
ASX Announcements
Annual & Financial Reports
Presentations
Share Price Information
AGM
INOVIQ Fact Sheet
Corporate Governance
Shareholder Services
FAQ
Analyst Reports
News & Events
INOVIQ in the News
Conferences & Events
Contact
Contact Us
Subscribe to Email Alerts
ASX Announcements
Heading &
Sub-heading can be edited through HQI
Investors
>
ASX Announcements
Investor Overview
ASX Announcements
Annual & Financial Reports
Presentations
Share Price Information
AGM
INOVIQ Fact Sheet
Corporate Governance
Shareholder Services
FAQ
Analyst Reports
ASX Announcements
Filter by Year:
2024
2023
2022
2021
2020
2019
2018
13-Apr-2021
BARD1 Signs Option Agreement for Type 3C Diabetes Test
19-Mar-2021
Appendix 2A
16-Mar-2021
Positive Results Evaluation of EXO-NET in Pancreatic Cancer
15-Mar-2021
Appendix 2A
15-Mar-2021
Australian Patent Granted for hTERT
12-Mar-2021
BARD1 Achieves hTERT Registration and First Order in Korea
2-Mar-2021
Appendix 2A
1-Mar-2021
Change in substantial holding
1-Mar-2021
Ceasing to be a substantial holder
26-Feb-2021
Appendix 4D and Half-year financial report
Previous
1
2
3
4
5
6
7
8
9
Next
